A Role for Extracellular Vesicles in SARS-CoV-2 Therapeutics and Prevention
Author
Machhi, JatinShahjin, Farah
Das, Srijanee
Patel, Milankumar
Abdelmoaty, Mai Mohamed
Cohen, Jacob D
Singh, Preet Amol
Baldi, Ashish
Bajwa, Neha
Kumar, Raj
Vora, Lalit K
Patel, Tapan A
Oleynikov, Maxim D
Soni, Dhruvkumar
Yeapuri, Pravin
Mukadam, Insiya
Chakraborty, Rajashree
Saksena, Caroline G
Herskovitz, Jonathan
Hasan, Mahmudul
Oupicky, David
Das, Suvarthi
Donnelly, Ryan F
Hettie, Kenneth S
Chang, Linda
Gendelman, Howard E
Kevadiya, Bhavesh D
Date
2021-02-05Journal
Journal of NeuroImmune PharmacologyPublisher
Springer NatureType
Article
Metadata
Show full item recordAbstract
Extracellular vesicles (EVs) are the common designation for ectosomes, microparticles and microvesicles serving dominant roles in intercellular communication. Both viable and dying cells release EVs to the extracellular environment for transfer of cell, immune and infectious materials. Defined morphologically as lipid bi-layered structures EVs show molecular, biochemical, distribution, and entry mechanisms similar to viruses within cells and tissues. In recent years their functional capacities have been harnessed to deliver biomolecules and drugs and immunological agents to specific cells and organs of interest or disease. Interest in EVs as putative vaccines or drug delivery vehicles are substantial. The vesicles have properties of receptors nanoassembly on their surface. EVs can interact with specific immunocytes that include antigen presenting cells (dendritic cells and other mononuclear phagocytes) to elicit immune responses or affect tissue and cellular homeostasis or disease. Due to potential advantages like biocompatibility, biodegradation and efficient immune activation, EVs have gained attraction for the development of treatment or a vaccine system against the severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infection. In this review efforts to use EVs to contain SARS CoV-2 and affect the current viral pandemic are discussed. An emphasis is made on mesenchymal stem cell derived EVs’ as a vaccine candidate delivery system. Graphical Abstract: [Figure not available: see fulltext.]. © 2021, The Author(s)Keyword
Coronavirus disease 2019 (COVID-19)Extracellular vesicles (EVs)
Mesenchymal stem cells (MSCs)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Identifier to cite or link to this item
http://hdl.handle.net/10713/14743ae974a485f413a2113503eed53cd6c53
10.1007/s11481-020-09981-0
Scopus Count
Related articles
- COVID-19 and Extracellular Vesicles: An Intriguing Interplay.
- Authors: Pocsfalvi G, Mammadova R, Ramos Juarez AP, Bokka R, Trepiccione F, Capasso G
- Issue date: 2020
- Mesenchymal stem cell derived extracellular vesicles: promising immunomodulators against autoimmune, autoinflammatory disorders and SARS-CoV-2 infection.
- Authors: Bulut Ö, GÜrsel İ
- Issue date: 2020
- Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19.
- Authors: Kumar S, Zhi K, Mukherji A, Gerth K
- Issue date: 2020 Apr 26
- The Role of Extracellular Vesicles as Allies of HIV, HCV and SARS Viruses.
- Authors: Giannessi F, Aiello A, Franchi F, Percario ZA, Affabris E
- Issue date: 2020 May 22
- Mechanistic and Therapeutic Implications of Extracellular Vesicles as a Potential Link Between Covid-19 and Cardiovascular Disease Manifestations.
- Authors: Pironti G, Andersson DC, Lund LH
- Issue date: 2021